Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. It is currently being evaluated in four clinical programs: systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.